Cover Image

Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53

Saved in:

Bibliographic Details
Main Authors:	Xiangbing Meng (Author), Don S. Dizon (Author), Shujie Yang (Author), Xinjun Wang (Author), Danlin Zhu (Author), Kristina W. Thiel (Author), Kimberly K. Leslie (Author)
Format:	Book
Published:	Hindawi Limited, 2013-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy through Synergistic Integration with Chemotherapy Drugs
by: Yajing Du, et al.
Published: (2023)

Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy
by: Kailin Li, et al.
Published: (2021)

Epigenetic based synthetic lethal strategies in human cancers
by: Aiai Gao, et al.
Published: (2020)

Targeting mutant p53 stabilization for cancer therapy
by: Jiajian Wang, et al.
Published: (2023)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
by: Victor M. Matias-Barrios, et al.
Published: (2023)

Studying synthetic lethal interactions in the zebrafish system: insight into disease genes and mechanisms
by: Vinita A. Hajeri, et al.
Published: (2012)

Reactivation of mutant p53 in esophageal squamous cell carcinoma by isothiocyanate inhibits tumor growth
by: Lulu Guan, et al.
Published: (2023)

Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins
by: Giovanni Blandino
Published: (2016)

Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish
by: Seok-Hyung Kim, et al.
Published: (2013)

Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
by: Phong Lu, et al.
Published: (2019)

Modified Gold Nanoparticles to Overcome the Chemoresistance to Gemcitabine in Mutant p53 Cancer Cells
by: Eduardo García-Garrido, et al.
Published: (2021)

Past, present, and future of hormonal therapy in recurrent endometrial cancer
by: Carlson MJ, et al.
Published: (2014)

Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
by: Marisa C Liu, et al.
Published: (2018)

Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells
by: Baoyuan Zhang, et al.
Published: (2020)

MPASL: multi-perspective learning knowledge graph attention network for synthetic lethality prediction in human cancer
by: Ge Zhang, et al.
Published: (2024)

Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells
by: Qianye Yang, et al.
Published: (2021)

EXP2SL: A Machine Learning Framework for Cell-Line-Specific Synthetic Lethality Prediction
by: Fangping Wan, et al.
Published: (2020)

Humanized yeast genetic interaction mapping predicts synthetic lethal interactions of FBXW7 in breast cancer
by: Morgan W. B. Kirzinger, et al.
Published: (2019)

Tumor grade and chemotherapy response in endometrioid endometrial cancer
by: Brittany A. Davidson, et al.
Published: (2016)

Immunoexpression of p53 mutant-type in Iranian patients with primary and recurrence oral squamous cell carcinoma
by: Hossein Daneste, et al.
Published: (2022)

Synthetic Lethal Activity of Benzophenanthridine Alkaloids From Zanthoxylum coco Against BRCA1-Deficient Cancer Cells
by: Iris A. García, et al.
Published: (2020)

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
by: Laurie Freire Boullosa, et al.
Published: (2023)

Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features
by: Eun Young Kang, et al.
Published: (2022)

Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib
by: Hua-Li Wang, et al.
Published: (2022)

The use of neoadjuvant chemotherapy in advanced endometrial cancer
by: L. Philp, et al.
Published: (2021)

Estudo anatomoclínico da expressão do p53 no adenocarcinoma de endométrio Clinical and pathological study of p53 expression in endometrial adenocarcinoma
by: Ângela Favorito Santarém Tonon
Published: (2007)

Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core
by: Daniil R. Bazanov, et al.
Published: (2022)

RUNX2 Reverses p53-Induced Chemotherapy Resistance in Gastric Cancer
by: Huang Y, et al.
Published: (2023)

In Vitro Assessment of the Role of p53 on Chemotherapy Treatments in Neuroblastoma Cell Lines
by: Idoia Blanco-Luquin, et al.
Published: (2021)

Adjuvant and first line chemotherapy use for endometrial cancer
by: Anne Knisely, et al.
Published: (2022)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)

Lethal Clostridium difficile Colitis Associated with Paclitaxel and Carboplatin Chemotherapy in Ovarian Carcinoma: Case Report and Review of the Literature
by: V. Masciullo, et al.
Published: (2010)

A rare case of lethal midline granuloma posing a diagnostic challenge in COVID times and the response to chemotherapy
by: Ajeet Singh, et al.
Published: (2022)

To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma
by: Anuja Yadav, et al.
Published: (2024)

LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer
by: Xiangfeng Meng, et al.
Published: (2020)

LETHAL CONCENTRATION OF Saussurea costus WITH BRINE SHRIMP LETHALITY TEST METHOD
by: Dhigna Luthfiyani Citra Pradana, et al.
Published: (2023)

Splice‐switch oligonucleotide‐based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC‐driven hepatocellular carcinoma
by: Dexter Kai Hao Thng, et al.
Published: (2023)

An evaluation of prevention initiatives by 53 national anti-doping organizations: Achievements and limitations
by: Katharina Gatterer, et al.
Published: (2020)

Lethal Midline Granuloma
by: Ghosh S.N, et al.
Published: (1995)

Lethal midline granuloma
by: Varuna Mallya, et al.
Published: (2013)